Levodopa fractionated dose composition and use

1. A method for the treatment of Parkinson's disease or related levodopa (LD)-responsive disorders, comprising orally administering to a patient in need thereof, carbidopa/levodopa (CD/LD) at an effective dose selected from the group consisting of carbidopa—6.25 mg/levodopa—25 mg and carbidopa—12.5 mg/levodopa—50 mg, to simulate continuous intravenous administration of LD, up to 9 times per day;

wherein the CD/LD are present in a total carbidopa—25 mg/levodopa—100 mg amount in a multiscore, bilayered tablet formed by a fully scored top layer, and divided by three scores providing four sections; that is adjoined to an inert, bottom layer comprising a pharmaceutical carrier without active ingredients;

wherein each score of the fully scored top layer partially penetrates the inert, bottom layer; and

wherein each of the four sections of the fully scored top layer comprises carbidopa—6.25 mg and levodopa—25 mg.

2. The method of claim 1 , wherein the patient is administered from one to six unit doses as the effective dose, each unit dose comprising a carbidopa—6.25 mg/levodopa—25 mg and the effective dose is administered from 5 times to 9 times per day.

3. The method of claim 1 , wherein said patient is a newly diagnosed patient at the initial stage of Parkinson's disease.

4. The method of claim 1 , wherein said patient is a parkinsonian patient previously administered a standard treatment with carbidopa/levodopa (CD/LD).

5. The method of claim 4 , wherein said patient suffers from Motor Response Complications.

6. The method of claim 2 , wherein said unit dose is carbidopa—6.25 mg/levodopa—25 mg, as a section of a three-score/four-section of the multiscore, bilayered tablet formed by the fully scored top layer comprising carbidopa, in a total amount of 25 mg, and levodopa, in a total amount of 100 mg, in admixture with a pharmaceutical carrier for immediate release.

7. The method of claim 1 , wherein one or more section is administered as a single unit dose from 5 to 9 times per day.

8. The method of claim 7 , wherein one or more section is administered as a single unit dose from 5 to 6 times per day.

9. The method of claim 1 , wherein the effective dose to simulate continuous intravenous administration of LD provides a constant plasma concentration range of the LD for full efficacy with no motor response complications.

10. A multiscore, bilayered tablet formed by a fully scored top layer containing a carbidopa (CD)-25 mg/levodopa (LD)-100 mg amount, in admixture with a pharmaceutical carrier for immediate release, and divided by three scores providing four sections; that is adjoined to an inert, bottom layer comprising a pharmaceutical carrier without active ingredients;

wherein each score of the fully scored top layer partially penetrates the bottom inert layer; and

wherein each of the four sections of the fully scored top layer contains carbidopa—6.25 mg and levodopa—25 mg.

11. The multiscore, bilayered tablet of claim 10 , wherein the carbidopa and levodopa are formulated in an orally disintegrable formulation.

12. A method for the treatment of Parkinson's disease or levodopa (LD)-responsive disorders in a patient who is hypersensitive to LD, comprising orally administering to the patient, carbidopa/levodopa (CD/LD) at an effective dose selected from the group consisting of carbidopa—6.25 mg/levodopa—25 mg and carbidopa—12.5 mg/levodopa—50 mg to simulate continuous intravenous administration of LD, up to 9 times per day,

wherein the CD/LD are present in a total carbidopa—25 mg/levodopa—100 mg amount in a multiscore, bilayered tablet formed by a fully scored top layer, in admixture with a pharmaceutical carrier, and divided by three scores providing four sections; that is adjoined to an inert, bottom layer comprising a pharmaceutical carrier without active ingredients;

wherein each score of the fully scored top layer partially penetrates the inert, bottom layer;

wherein each of the four sections of the fully scored top layer comprises carbidopa—6.25 mg and levodopa—25 mg.

13. The method of claim 12 , wherein the patient is a minor child.

14. The method of claim 12 , wherein the LD-responsive disorder is generalized dystonia.

15. The method of claim 12 , wherein the carbidopa/levodopa is administered two times a day (b.i.d.) or three times a day (t.i.d.).

16. The method of claim 12 , wherein the effective dose of carbidopa—12.5 mg/levodopa—50 mg is administered two times a day (b.i.d.).

17. A method of treating or alleviating motor response complications related to Parkinson's disease or related levodopa (LD)-responsive disorder, comprising orally administering to a patient in need thereof, carbidopa/levodopa (CD/LD) at an effective dose selected from the group consisting of carbidopa—6.25 mg/levodopa—25 mg and carbidopa—12.5 mg/levodopa—50 mg, to simulate continuous intravenous administration of LD, up to 9 times per day,

wherein the CD/LD are present in a total carbidopa—25 mg/levodopa—100 mg amount in a multiscore, bilayered tablet formed by a fully scored top layer, and divided by three scores providing four sections; that is adjoined to an inert, bottom layer comprising a pharmaceutical carrier without active ingredients;

wherein each score of the top, fully scored layer partially penetrates the inert, bottom layer; and

wherein each of the four sections of the fully scored top layer comprises carbidopa—6.25 mg and levodopa—25 mg.

18. The method of claim 17 , wherein one or more section is administered as a single unit dose from 5 to 9 times per day.

19. The method of claim 18 , wherein one or more section is administered as a single unit dose from 5 to 6 times per day.

20. The method of claim 17 , wherein the effective dose to simulate continuous intravenous administration of LD provides a constant plasma concentration range of the LD for full efficacy with no motor response complications.